Delivering Diagnostics that Improve Patient Care

GenMark DiagnosticsDelivering Diagnostics that Improve Patient Care

November 2020

Forward-Looking Statement

This presentation contains forward-looking statements about GenMark Diagnostics, Inc. These statements involve known and unknown risks that relate to the Company’s future events or

future financial performance and the actual results could differ materially from those discussed in this presentation. Factors that may cause the Company's actual results to differ materially

from those discussed in the presentation, include:

• failure of the Company’s products to gain market acceptance domestically or internationally;

• failure to scale our manufacturing operations to sufficiently support our anticipated future growth;

• the refusal of third-party payors to reimburse the Company’s customers for use of diagnostic systems and tests;

• the loss of the Company’s largest customer;

• the Company’s history of net losses;

• increases in the Company’s projected expenditures on sales and marketing, research and development and administrative activities;

• less than anticipated growth in the market for diagnostic testing generally and for the tests the Company is developing or may develop in the future;

• inability to obtain regulatory clearance or approval for any of the Company’s products;

• changes in the regulatory environment which may adversely impact the commercialization of the Company’s new products and result in significant additional

capital expenditures;

• failure to enter into or maintain successful strategic alliances, which may delay the development or commercialization of the Company’s products or may result in significant additional

expenditures;

• failure to obtain sufficient funding for the continued development and commercialization of the Company’s products;

• inability to attract or retain skilled personnel for the Company’s product development and commercialization efforts; and

• inability to protect the Company’s intellectual property and operate the Company’s business without infringing upon the intellectual rights of others, which could result in litigation and

significant expenditures.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of GenMark’s most recent Annual Report on Form 10-K, Quarterly Report

on Form 10-Q, and other filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation represent the Company’s estimates

and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this

presentation as a result of new information, future events, or changes in the Company’s expectations.

© Copyright 2020 GenMark Diagnostics, Inc. All rights reserved. 2

Recent Highlights


✓ 2020 revenue guidance increased from $155 - $165M to $165M - $168M

✓ Commercial launch of ePlex Respiratory Pathogen Panel 2 (RP2)

✓ Received Emergency Use Authorization (EUA) for ePlex Respiratory Pathogen Panel 2 (RP2)

70net new systems

115+ new customers YTD

$6.3Mcash from operations

$193Kaverage annual

annuity/placement

Q3 Highlights:


Improving Patient Care with Multiplex Molecular Diagnostics

Simple, rapid

and actionableDifferentiated

ePlex® platform

Comprehensive

Pathogen Coverage

Delivering growth +

margin expansion

$

Multiplex molecular

diagnostics to help

improve management

of high-risk patients

Highly scalable

“sample-to-answer”

solution with simplest

workflow

Proven ability to drive

revenue, improve

gross margins,

generate cash

Unique blood culture

ID solution and

sustained leadership

in respiratory testing

5

ePlex: The True Sample-to-Answer Solution® (< 2h)

Load Sample Insert Cartridge Report Results

Conventional Molecular Testing (~6-24h+)

Extraction Formulation Amplification Detection Report ResultsSample Preparation

© Copyright 2020 GenMark Diagnostics, Inc. All rights reserved.

Proprietary Technologies Enable ePlex Sample-to-Answer SolutionMakes complex multiplex molecular diagnostics accessible in new care settings

http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=pE_8aS9yeFkODM&tbnid=BvzOEUT7RLzJqM:&ved=0CAUQjRw&url=http://www.ilexmedical.com/products.php?id=62&ei=3HDkUb_9KYa0iwLp64DIBg&bvm=bv.48705608,d.cGE&psig=AFQjCNHVXXNF8DZKRn5wIZJxEkqONd6Zwg&ust=1374011990491372

http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=FbCJFhdhqLEidM&tbnid=u6JPrx5BddSemM:&ved=0CAUQjRw&url=http://www.sci-support.com/items/Applied-Biosystems-PCR-GeneAmp-9700-Thermocycler-1464.htm&ei=kHPkUeSPA8LliALWwoHoDA&bvm=bv.48705608,d.cGE&psig=AFQjCNEM84PURBysviYAxZeYsXuqNWh-DA&ust=1374012680570357

Management estimates subject to change


$600M+

$140M

$500M+

$450M+

$900M+

Blood Culture ID

Meningitis / Encephalitis

Hepatitis C Genotyping

Other:

MDRO, PJI, SSTI

$100M

Respiratory:

RP and Pneumonia

Gastrointestinal

202020192018 2021 2022

~$1B

Significant Global Market Opportunity for Multiplex Testing$2.5B+ infectious disease market less than 40% penetrated

Market PenetrationTotal Addressable Market

Designed for the Patient,

Optimized for the Lab®

The ePlex System is designed to

improve patient outcomes and

reduce hospital costs


GenMark is Uniquely Positioned to Win


IT Integration

• Advanced LIS and integration capabilities provide significant

productivity gains

• Integrated software to link diagnostic results to actionable therapy

Order-to-Report

Efficiency

• Minimal hands-on-time and scalable throughput for managing peak

testing demand

• Simplest workflow enables high-throughput & reduces labor costs

Patient Centered

Care

• Comprehensive pathogen coverage ensures clinically relevant results

• Positive patient ID capabilities designed to reduce avoidable medical

errors and ensure patient safety

Scalable Design Extends ePlex Benefits Across All Segments


Small Rural

Hospitals

Community

Hospitals

Commercial

Reference LabsLarge Academic Centers

and Hospital Systems

Sam

ple

s p

er

8 H

our

Shift

96

72

48

24

12

2017

51 82

147196

Q1 Q2 Q3 Q4

2018

228267

312354

Q1 Q2 Q3 Q4

2019

393438

489527

Q1 Q2 Q3 Q4

Q3’20 analyzer annuity of $193,000

Growing Installed Base and Increasing Annuity Drives Growth

Cum

ula

tive e

Ple

x A

naly

zers

10 © Copyright 2020 GenMark Diagnostics, Inc. All rights reserved.

2020

581

Q1 Q2Q3 Q4Q2

652

Q3

722

Global Opportunities

11

Targeting additional markets in Middle East, Asia Pacific and Latin America

‒ Direct Sales

‒ Distributors

‒ New market expansion

GenMark Commercial Presence:

• 20 United States Territories

• 10 Field Technical Specialists

• 5 Member Strategic Account Team

• 3 Infectious Disease Specialists

• 25 Distributor Partners in Europe and

certain other geographic regions



Addressing the Need for Rapid DiagnosticsRespiratory Infections

More doctor visits and absences from school and work than any other illness1

~500 millionNon-influenza infections annually in the U.S.1,2,3

Traditional Diagnostic Methods

Can delay results by 8-72 hours and

miss >80% of viruses and bacteria that can cause influenza-like illness4

Rapid diagnostic tests can reduce mortality in high-risk groups

The ePlex Respiratory Pathogen PanelsDriving consistent year-over-year growth


RP Panel detects >20 common respiratory pathogens5

• Achieved CE Mark in Q2 2016 and FDA Clearance in Q2 2017

RP2 & SARS-CoV-2 test launched under FDA EUA

• Rapid response to COVID 19 global pandemic with streamlined workflow

Validated clinical performance (RP Panel)

• U.S. clinical study showed 95.2% agreement with comparator method in

3,235 samples6

Rapid, accurate, actionable results inform patient care

• Established standard-of-care for high-risk patients makes RP the largest

multiplex market segment in the world


Addressing the Need for Rapid DiagnosticsBloodstream Infections and Sepsis

~30,000,000 affected globally every year7

Most expensive condition in hospitals:

~$18,000 per case8 causing a

death every 4 seconds9

Sepsis mortality increases up to

8%every hour effective

antibiotics are delayed10

10 million

peopleestimated to die

annually due to

antimicrobial resistant

infections by 205011

15Detection rate is based on panel inclusivity only and is not a sensitivity/performance claim.


ePlex Blood Culture Identification PanelsDriving the next phase of growth

Unique Assay Design

• 10-20% more organism coverage than comparable panels12-13

• Includes potentially fatal fungal organism C. auris

Rapid Actionable Results

• Results within two hours of confirming a bloodstream infection

• Appropriate therapy sooner with broadest resistance gene coverage

Software Integration Optimizes Patient Care

• Unique antimicrobial stewardship module

• Alert notifications help eliminate patient treatment delays

Instrument

Software v2.0


Investing in Innovation to Drive Sustained Long-Term Growth

2017 2018 2019 2020 2021+

RP Panel

FDA Clearance

BCID Panels

FDA Clearance CNS PanelIn Development

Instrument

Software v3.0

GI PanelIn Development

ePlex System

FDA Clearance

Ongoing Platform

Development and

Menu ExpansionSARS-CoV-2 EUA Clearance

RP2 PanelCommercial Launch

Instrument

Software v2.5


Accelerate BCID Launch and Extend RP Leadership

2020 Action Plan

Continue to focus on panel

utilization to accelerate revenue

Drive efficiency with optimized

commercial organization including

increases in Strategic Account

Team

Finalize contracts with leading

national IDNs and GPOs

BCID drove 80% of new customer

placements

> 300 new panels implemented

and pending implementation

Almost 50% of BCID placements

also include RP

2019 Accomplishments

1. XT-8 gross margin based on 2011-2016 results. Year 3 XT-8 gross margin results were 47% on a non-GAAP basis related to certain one-time charges

2. ePlex gross margin based on 2018-2020 results and may not be indicative of future performance


Drive ePlex Gross Margin Expansion

GenMark Product Gross Margin Trajectory

-30%

-20%

-10%

0%

10%

20%

30%

40%

50%

60%

70%

Year 1 Year 2 Year 3 Year 4 Year 5

ePlex

XT-8

History of driving significant

gross margin improvements

Improved ePlex gross margin by

5 points over Q3’19 to 39%

Goal to exit 2022 with 60%

ePlex gross margin

ePlex

Target


Deliver on Innovation Agenda

Deliver ePlex Menu

• Launched RP2 incorporating COVID-19

• Execute GI product development and clinical study

• Complete technology development for future panels

Elevate Manufacturing Capabilities

• Continuous improvement manufacturing processes

• Expanded ePlex manufacturing capacity to support demand

Leverage Technology and Commercial Execution

• Capitalize on market position within the broader strategic

landscape

Total Revenue

YoY

$38.7M

~80%

$40.1M

~118%

ePlex Revenue

YoY

$34.3M

~119%

$35.2M

~195%

20

2020 Quarterly Results

Q1 2020 Q2 2020

Net Placements

Installed Base

54 (109 gross)

581

71 (89 gross)

652

Gross Margin

YoY

41.6%

14.5 ppts

39.5%

3.7 ppts

Operating cash $47.1M $132.8M

~104%

Q3 2020

~187%

722

5.1 ppts

70 (86 gross)

$42.6M

$38.0M

38.8%

$137.3M

21

2020 Revised Guidance

Total Revenue

Gross Margin

Net Placements

Operating Expenses

$165 to $168 million

38% to 40%

230 to 250 net new analyzersAnnuity per ePlex Analyzer of $175 to $200 thousand

$70 to $75 million

Cash Usage (excl. Financing) $10 to $15 million


References

1. Upper Respiratory Infection (URI or Common Cold). Johns Hopkins Medicine. Retrieved from http://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/upper_respiratory_infection_uri_or_common_cold_90,P02966/ (Date accessed: May 2017)

2. The Common Cold Fact Sheet. National Institute of Allergy and Infectious Diseases, National Institutes of Health. December 2004.

3. Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 163(4):487-94.

4. Antigen detection, DFA, culture and batch PCR delay treatment decisions based on batch methods run once per day often excluding weekends.

5. CE-IVD RP Panel also detects Human Bocavirus, Middle East Respiratory Syndrome Coronavirus, Bordetella pertussis, Legionella pneumophila

6. ePlex RP package insert. After discordant resolution. May 2017

7. V2_Sepsis Fact Sheet. World Sepsis Day. Global Sepsis Alliance. Center for Sepsis Control & Care.

8. H-Cup Statistical Brief #204: May 2016

9. Institut Pasteur, Sepsis/Septicemia; https://www.pasteur.fr/en/medical-center/disease-sheets/sepsis-septicemia.

10. Kumar, et. al., Crit Care Med 2006 Vol. 34, No. 6. p. 1589-1596.

11. Review on antimicrobial resistance. Chaired by Jim O’Neill. Dec. 2014.

12. Potula, R., Dadhania, V., & Truant, A. L. (2015). Automated blood culture testing. MLO: Medical Laboratory Observer, 47(9), 8-14.

13. Analyses from GenMark clinical data and data from 5 US hospitals.


Documents

Delivering Diagnostics that Improve Patient Care